Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Buys $2,999,999.25 in Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) major shareholder Paul B. Manning acquired 1,333,333 shares of the firm’s stock in a transaction on Thursday, June 27th. The stock was bought at an average price of $2.25 per share, with a total value of $2,999,999.25. Following the completion of the acquisition, the insider now directly owns 1,333,333 shares in the company, valued at approximately $2,999,999.25. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock traded up $0.04 during trading hours on Monday, reaching $2.28. The company had a trading volume of 365,366 shares, compared to its average volume of 2,750,745. The business has a fifty day moving average price of $2.97 and a 200-day moving average price of $2.42. Taysha Gene Therapies, Inc. has a one year low of $0.61 and a one year high of $4.32. The firm has a market cap of $426.41 million, a PE ratio of -4.57 and a beta of 0.42. The company has a debt-to-equity ratio of 0.75, a quick ratio of 3.38 and a current ratio of 3.38.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The firm had revenue of $3.41 million during the quarter, compared to analyst estimates of $3.70 million. During the same period in the previous year, the business posted ($0.28) earnings per share. Sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on TSHA. Canaccord Genuity Group restated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 21st. JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Piper Sandler decreased their price objective on shares of Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating for the company in a report on Monday. Chardan Capital restated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, June 18th. Finally, Needham & Company LLC reissued a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Monday, June 17th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies has a consensus rating of “Buy” and an average price target of $6.60.

Institutional Trading of Taysha Gene Therapies

Several large investors have recently added to or reduced their stakes in TSHA. Schonfeld Strategic Advisors LLC bought a new stake in Taysha Gene Therapies during the third quarter valued at approximately $2,275,000. Adage Capital Partners GP L.L.C. bought a new stake in Taysha Gene Therapies during the third quarter valued at approximately $4,740,000. Acuta Capital Partners LLC bought a new stake in Taysha Gene Therapies during the third quarter valued at approximately $12,096,000. Kynam Capital Management LP bought a new stake in Taysha Gene Therapies during the third quarter valued at approximately $10,369,000. Finally, RTW Investments LP bought a new stake in Taysha Gene Therapies during the third quarter valued at approximately $53,382,000. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.